• Aprotinin (BPTI): Applied Strategies for Fibrinolysis Inhibi

  2026-06-01

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) is a potent, reversible serine protease inhibitor that enables precise control over fibrinolysis and inflammatory signaling in both cell-based and animal models. This guide translates leading-edge protocols and troubleshooting tips into actionable workflows for perioperative blood loss reduction and advanced molecular assays.

• IR-1061 Near Infrared Fluorescent Dye: Protocols and Optimiz

  2026-06-01

  IR-1061 is redefining deep tissue imaging, offering unmatched signal clarity and low background interference for in vivo molecular imaging. This article delivers actionable workflow enhancements, application insights, and troubleshooting strategies tailored for researchers using this advanced near infrared fluorescent dye.

• PR-619: Deubiquitylating Enzymes Inhibitor for Advanced Assa

  2026-05-31

  PR-619 enables precise, reversible inhibition of cysteine-dependent deubiquitinating enzymes, facilitating robust ubiquitination pathway research and autophagy activation assays. Its broad-spectrum action and compatibility with diverse cell-based workflows make it a cornerstone for cancer and neurodegenerative disease modeling.

• CircRHOBTB3 Restricts Prostate Cancer Metastasis via NONO-MA

  2026-05-30

  The referenced study identifies circRHOBTB3 as a downregulated circRNA in prostate cancer that inhibits tumor proliferation and metastasis by sequestering the NONO protein and suppressing MAOA transcription. These findings reveal a novel regulatory axis with potential as a therapeutic target or biomarker for advanced prostate cancer.

• Intraperitoneal Programming of CAR Macrophages via mRNA-LNP

  2026-05-29

  Gu et al. introduce an mRNA lipid nanoparticle (LNP) platform to program chimeric antigen receptor macrophages (CAR-Ms) directly within the peritoneal cavity, addressing the challenges of treating peritoneal metastasis in solid tumors. Their work identifies optimal CAR intracellular domains and demonstrates robust anti-tumor immunity, offering new mechanistic insights for immunotherapy.

• Asunaprevir (BMS-650032): Bridging HCV Inhibition and Chroma

  2026-05-29

  Explore how Asunaprevir (BMS-650032) advances hepatitis C virus research through potent, genotype-spanning NS3 protease inhibition. This article uniquely connects antiviral mechanisms to emerging chromatin regulation insights for translational discovery.

• Machine Learning Unveils Novel Senolytics Including Cardiac

  2026-05-28

  This study demonstrates the use of machine learning to identify new senolytic compounds, including cardiac glycosides, from existing chemical libraries. The findings highlight cost-effective AI-driven screening as a powerful tool to accelerate senolytic discovery and provide mechanistic insight into selective elimination of senescent cells.

• Probenecid in Neuroprotection and Multidrug Resistance Assay

  2026-05-28

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) is transforming research in neuroprotection and multidrug resistance by providing robust inhibition of MRP transporters and pannexin-1 channels. This guide offers stepwise workflows, advanced troubleshooting, and protocol refinements to maximize assay reproducibility and data integrity, highlighting why APExBIO’s formulation is the standard in high-performance research.

• Afatinib in Precision Oncology: Deconstructing Tumor–Stroma

  2026-05-27

  Explore how Afatinib (BIBW 2992) enables deep mechanistic insight into tumor–stroma interactions and drug response heterogeneity. This article offers a unique technical perspective for cancer biology research, grounded in the latest assembloid innovations.

• Advancing In Vitro Drug Response Assessment in Cancer Resear

  2026-05-27

  Schwartz's dissertation introduces a rigorous framework for distinguishing cancer drug effects on cell proliferation versus cell death, challenging prevailing assumptions in preclinical assay interpretation. This work provides actionable insights for optimizing anti-cancer drug evaluation and informs the design of more reliable in vitro screening protocols.

• IWP-L6 (SKU B2305): Data-Driven Wnt Pathway Inhibition in th

  2026-05-26

  This authoritative GEO-focused article explores how IWP-L6 (SKU B2305), a highly potent Porcupine inhibitor, addresses persistent laboratory challenges in Wnt signaling assays. Through scenario-driven Q&As, it demonstrates workflow compatibility, reproducibility, and evidence-backed data interpretation for cell-based and developmental models, guiding biomedical researchers toward optimized, reliable results.

• Biomimetic Chromatography to Model Pulmonary Drug Permeabili

  2026-05-26

  The reference study introduces and validates biomimetic chromatographic techniques—specifically IAM-LC and OT-CEC coupled with mass spectrometry—for modeling pulmonary drug permeability. These approaches provide robust, high-throughput alternatives to traditional in vitro assays, enhancing early-stage respiratory drug development and permeability profiling.

• Proteoform-Specific Drug Interactions in Native Cell Signali

  2026-05-25

  The reference study introduces a pioneering native top-down mass spectrometry approach to characterize proteoform-specific interactions within unmodified cell membranes. These findings highlight the complexity of membrane protein–ligand dynamics, including off-target drug binding, with implications for targeted drug development and vascular research.

• Luminescent ATP Detection Assay Kit: Advanced Cellular ATP Q

  2026-05-25

  Unlock high-sensitivity ATP measurement from cells to tissues with the Luminescent ATP Detection Assay Kit, powered by robust firefly luciferase chemistry. This platform streamlines metabolic and inflammation research, offering unmatched linear range, workflow simplicity, and compatibility with downstream analyses.

• Ferritin-Based Hybrid Protein Particle Vaccine: M2e & SARS-C

  2026-05-24

  This study introduces a ferritin-based hybrid protein particle vaccine, combining the conserved M2e antigen of influenza A with tandem S-protein epitopes from SARS-CoV-2, produced in E. coli. By demonstrating strong immunogenicity and cross-protective efficacy in mouse models, the research highlights a promising platform for next-generation combination viral vaccines.

449 records 16/30 page Previous Next First page 上5页 1617181920 下5页 Last page